Search Results

such as ipilimumab and vemurafenib in 2011, we analyzed the median OS difference before (2004–2010) and after 2011 (2012–2015) in T3 facilities and found that the median OS for patients with stage IV disease managed at T3 facilities after 2011 was

,074); however, this analysis was driven by the costs of interleukin-2, alternate systemic therapies (ipilimumab and vemurafenib), isolated limb infusion, and radiation. Median ICER of new drugs compared with controls was $186,403 (range, $7

-positive melanoma of skin involving left anterior chest wall, pleura, and inguinal lymph node, which was diagnosed 2 years before his presentation to the emergency room. When the disease progressed after therapy with vemurafenib and a high dose of interleukin-2, the

survival, from PROFILE 1001. Ann Oncol 2019 ; 30 : 1121 – 1126 . 30980071 2. Dummer R , Ascierto PA , Gogas HJ , . Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib

-naïve patients harboring the V600E mutation, and 31% in previously treated patients with the mutation. 87 Case reports have also shown promising results for the BRAF inhibitor vemurafenib in brain metastases. 88 Ipilimumab, an anti-CTLA4 monoclonal antibody

trials can make important strides in the overall understanding of biomarkers in cancer care and contribute to precision medicine. BRAF V600 mutations occur in various nonmelanoma cancers, and Hyman et al 8 sought to explore the use of vemurafenib

testing is increasingly being used to direct cancer treatment, increasing the probability that patients will benefit from therapy. The recent FDA approval of vemurafenib, a treatment for late-stage melanoma, simultaneously with a companion diagnostic (the

.1177/1078155220953877 15. Janson B , Whittle J , Witney K , Use of vemurafenib in a patient unable to swallow whole . J Oncol Pharm Pract 2016 ; 22 : 733 – 737 . 10.1177/1078155215603231 16. Arnold-Korzeniowsk K . Trametinib (Mekinist

Therefore, imatinib is reasonable to use in patients with MM who have c-KIT mutations. 52 Although vemurafenib is recommended for patients with cutaneous melanoma who have the V600E mutation of the BRAF gene, patients with MM rarely have this BRAF

BRAF-mutated melanoma . N Engl J Med 2017 ; 377 : 1813 – 1823 . 10.1056/NEJMoa1708539 28891408 7. Maio M , Lewis K , Demidov L , Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised